Charting a Healthier Future: A Comprehensive Analysis of Economic and Commercial Determinants of Health in Small Island Developing States A newly released technical paper by the World Health Organization (WHO) marks a pivotal advancement in the global response to noncommunicable…
Alnylam Pharmaceuticals Unveils 2024 Corporate Responsibility Report, Showcasing Impact Across ESG Pillars Alnylam Pharmaceuticals, the industry leader in RNA interference (RNAi) therapeutics, has published its 2024 Corporate Responsibility Report, reaffirming its commitment to science, sustainability, equity, and ethical business conduct.…
BioNTech Strengthens Partnership with UK Government to Significantly Expand Regional Research and Development Efforts BioNTech , a leading biotechnology firm recognized globally for its pioneering work in mRNA technology and immunotherapies, today announced a landmark agreement between its UK subsidiary,…
Merck and imec Forge Strategic Alliance to Revolutionize Drug Discovery Through Advanced Microphysiological Systems Merck, a global leader in science and technology, and imec, a premier international hub for research and innovation in nanoelectronics and digital technologies, have announced a…
Roche Provides Update on FDA Advisory Committee Review of Columvi Combination Therapy for Relapsed or Refractory DLBCL Roche has shared an important regulatory update concerning its investigational treatment for a particularly aggressive form of blood cancer. On May 21, 2025,…
GSK Secures Japanese Approval for Blenrep Combinations in Relapsed/Refractory Multiple Myeloma Based on Robust Phase III Data In a major advancement for the treatment landscape of multiple myeloma, GSK plc (LSE/NYSE: GSK) announced that Japan’s Ministry of Health, Labour and…
Regeneron to Acquire Core Assets of 23andMe for $256 Million in Bankruptcy Auction, Pledges to Preserve Consumer Genetics Mission and Strengthen Human Health Research In a major development within the biotechnology and genetics sectors, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has…
Daiichi Sankyo and Merck Launch Phase 3 IDeate-Esophageal01 Trial of Ifinatamab Deruxtecan in Advanced Esophageal Squamous Cell Carcinoma Daiichi Sankyo and Merck have officially initiated dosing in their pivotal Phase 3 clinical trial, named IDeate-Esophageal01, marking a significant step forward…
BioMarin Bolsters Enzyme Therapy Portfolio with $270 Million Acquisition of Rare Disease Specialist Inozyme Pharma BioMarin Pharmaceutical, a leading biotech company focused on rare diseases and enzyme replacement therapies, announced on Friday that it is acquiring Inozyme Pharma, a clinical-stage…
Global Youth Scientists Shine at 75th Regeneron ISEF, Sharing Over $9 Million in Prizes In a celebration of youthful brilliance, scientific curiosity, and international collaboration, the 75th Annual Regeneron International Science and Engineering Fair (ISEF) awarded over $9 million in…
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr), the First and Only Approved First-Line Treatment for Advanced Anal Cancer in the U.S. Incyte Corporation (Nasdaq: INCY), a global biopharmaceutical company focused on delivering innovative therapies for patients with serious diseases, today…
GSK Acquires Phase III-Ready Efimosfermin for $1.2 Billion in Bid to Transform Steatotic Liver Disease Treatment GSK has announced a major strategic acquisition in the field of hepatology, entering into a definitive agreement to acquire efimosfermin alfa, a potential best-in-class…